Navigation Links
Genesis Biopharma Announces $700K Private Financing
Date:9/23/2010

MANHATTAN BEACH, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it has closed a private offering pursuant to which it entered into definitive agreements with accredited investors to purchase 933,341 shares of its common stock at a purchase price of $0.75 per share, together with Series A warrants to purchase 466,674 shares at an exercise price of $1.00 per share, and Series B warrants to purchase 466,674 shares at $1.25 per share.  The private financing will provide gross cash proceeds to Genesis Biopharma, Inc. of approximately $700,000 from the sale of common stock and warrants.

"This financing signals an important next step," said Robert Brooke, President and CEO of Genesis Biopharma.  "We are now positioned to advance our anti-CD55 antibody program, which has shown strong potential for use as a targeted cancer therapy.  We also can aggressively pursue new opportunities through in-licensing and collaborations, making the upcoming months an exciting time."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the Company, visit http://www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect", "potential", "suggests", "may", "should", "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

ROBERT BROOKE

http://www.profnetconnect.com/robert_brooke


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New Canaan, CT (PRWEB) , ... March 29, 2017 , ... ... of antibiotics and hormones in the world’s food supply through enhancement of the gut ... in the round included Connecticut Innovations , New York-based Sustainable Income Capital Management, ...
(Date:3/29/2017)... 2017 /PRNewswire/ - The University of Missouri Research Reactor ... of Sterigenics International, and General Atomics (GA), announce that ... the U.S. Nuclear Regulatory Commission (NRC). This marks a ... (Mo-99). Once operational, production from this facility will be ... Mo-99, which currently must be imported from outside ...
(Date:3/29/2017)... -- The Global Microfluidic Chips Market by Manufacturers, Countries, ... comprehensive study on the existing state of the global Microfluidic Chips ... Europe and Asia-Pacific , ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Mass spectrometry is becoming more widely for clinical ... driven by its potential to perform challenging analyses in complex matrices and sample types. ... be addressed for it to be routinely used for medical testing. , ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
Breaking Biology News(10 mins):